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ABSTRACT
Introduction Septic shock is the subgroup of patients 
with sepsis, which presents as vasopressor dependence, 
an elevated blood lactate concentration and is associated 
with a mortality of at least 30%. Expression of the triggering 
receptor expressed on myeloid cells 1 (TREM-1) pathway, 
measured using a serum biomarker of pathway activation 
(soluble TREM-1, sTREM-1) has been associated with 
outcome in septic shock. Preclinical and early phase patient 
data suggest that therapeutic modulation of this pathway 
may improve survival.
Methods and analysis Efficacy, Safety and Tolerability 
of Nangibotide in Patients with Septic Shock is a phase IIb 
randomised controlled trial that will take place in up to 50 
centres in seven countries and recruit 450 patients with 
septic shock to receive either placebo or one of two doses of 
nangibotide, a novel regulator of the TREM-1 pathway. The 
primary outcome will be the impact of nangibotide therapy 
on the change in Sequential Organ Failure Assessment score 
from a baseline determined before initiation of study drug 
therapy. This will be assessed first in the patients with an 
elevated sTREM-1 level and then in the study population as a 
whole. In addition to safety, secondary outcomes of the study 
will include efficacy of nangibotide in relation to sTREM-1 
levels in terms of organ function, mortality and long- term 
morbidity. This study will also facilitate the development of a 
novel platform for the measurement of sTREM-1 at the point 
of care.
Ethics and dissemination The study has been approved 
by the responsible ethics committees/institutional review 
boards in all study countries: Belgium: Universitair Ziekenhuis 
Antwerpen, France: CPP Ile de France II, Denmark: Region 
Hovedstaden, Spain: ethics committee from Valld’Hebron 
Hospital, Barcelona, Finland: Tukija, Ireland: St. James’ 
Hospital (SJH) / Tallaght University Hospital (TUH) Joint 
Research Ethics Committee, USA: Lifespan, Providence
Trial registration numbers EudraCT Number: 2018-
004827-36 and NCT04055909.
INTRODUCTION
Sepsis is defined as a life- threatening condi-
tion arising as a result of the body’s dysreg-
ulated host response to infection.1 Septic 
shock is present in the subgroup of patients 
with sepsis, persistent hypotension requiring 
vasopressor support and an elevated serum 
lactate.2 This multisystem disorder is asso-
ciated with a 30% mortality and substantial 
morbidity including a higher risk of mortality 
during succeeding years,3 4 as well as cognitive 
and physical complications, immune dysfunc-
tion, secondary infections, persistent organ 
damage, impaired quality of life and depres-
sion or post- traumatic stress.5 6
The current recommendations for 
treatment of septic shock remain largely 
supportive7 in spite of extensive efforts to 
develop new therapies.8 9 Novel therapeutic 
approaches that have shown promise in 
Strengths and limitations of the study
 ► The multicentre Efficacy, Safety and Tolerability of 
Nangibotide in Patients with Septic Shock study will 
address the efficacy of a novel therapeutic agent 
nangibotide at two doses in improving acute mor-
bidity and mortality of patients with septic shock in 
up to 50 hospitals in at least six countries.
 ► The primary endpoint, the change in Sequential 
Organ Failure Assessment score from baseline to 
day 5 will offer insights into the impact of treatment 
on acute morbidity and provide a robust surrogate to 
facilitate design of future trials.
 ► The primary outcome will be assessed in patients 
with an elevated soluble triggering receptor ex-
pressed on myeloid cells 1 level (a marker of path-
way activation) and in the overall population
 ► Secondary outcomes will assess the impact of nan-
gibotide therapy on mortality and morbidity in septic 
shock.
 ► As a phase IIb trial, the study is not powered to 
detect an impact on mortality in septic shock and 
utilises a validated surrogate to detect clinically rel-
evant benefit.
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preclinical development have repeatedly failed in clin-
ical trial.10 This has led to recognition that conventional 
randomised controlled trial designs in sepsis may be inad-
equate for the development of new therapies and that 
new trial designs that target specific populations within 
the septic shock population are required.9 11
The triggering receptor expressed on myeloid cells 1 
(TREM-1) is an immunomodulatory receptor expressed 
on innate immune cells, endothelial cells and plate-
lets.12–15 The biological function of TREM-1 is the ampli-
fication of the inflammatory response. In sepsis, this may 
contribute to the dysregulated immune response,16 which 
plays a role in the development and progression of septic 
shock. Exaggerated activation of this pathway, measured 
by high circulating levels of expression of the cleaved 
portion of the receptor soluble TREM-1 (sTREM-1), is 
associated with increased mortality in patients with septic 
shock.17
Nangibotide is a 12 amino- acid peptidic fragment 
derived from TREM- like transcript-1, a receptor protein 
belonging to the TREM-1 family. Nangibotide can bind 
the TREM-1 ligand and thereby modulate the amplifica-
tion of the immune response caused by the activation of 
the TREM-1 pathway in sepsis.18 19
Extensive preclinical modelling in rodent, porcine and 
primate septic shock revealed a protective effect of nangi-
botide in terms of organ function, cardiovascular status 
and survival.20 21 A recent phase IIa clinical trial investi-
gated the safety and tolerability of three doses of nangi-
botide for up to 5 days in 49 patients with septic shock. In 
this trial, treatment with nangibotide was found to be safe 
and well tolerated. Although this study was not designed 
to prove efficacy, nangibotide treated patients demon-
strated numerical improvements in markers of organ 
function consistent with the hypothesis that TREM-1 inhi-
bition may improve outcomes in septic shock patients. 
This effect was larger in the subgroup of patients with 
high circulating levels of sTREM-1.22
We report the clinical and statistical design of the Effi-
cacy, Safety and Tolerability of Nangibotide in Patients 
with Septic Shock (ASTONISH), a randomised, double- 
blind, placebo- controlled dose selection phase IIb 
study in patients with septic shock. The study includes a 
number of innovative components to address the limita-
tions of previous studies in this area and a novel analytical 




 ► To evaluate the efficacy of two doses of nangibotide 
on organ dysfunction (Sequential Organ Failure 
Assessment, SOFA score) in patients with septic 
shock in relation to their sTREM-1 plasma levels 
(patients with high sTREM-1 levels at baseline and 
all patients).
Secondary
Secondary objectives of the study are to investigate the 
safety and efficacy of two doses of nangibotide in patients 
with septic shock in relation to their sTREM-1 levels.
This includes:
 ► To evaluate the effect of nangibotide on mortality for 
up to 12 months.
 ► To evaluate the effect of nangibotide on other clin-
ical parameters (eg, duration of shock, vasopressor 
use, ventilator and renal replacement use, secondary 
infections).
 ► To evaluate the safety and tolerability of nangibotide.
 ► To evaluate the effect of nangibotide on quality of life, 
resource utilisation and postshock morbidity.
Box 1 Inclusion and exclusion criteria for the Efficacy, 
Safety and Tolerability of Nangibotide in Patients with 
Septic Shock study
Inclusion criteria
 ► Provide written informed consent (proxy/legal representative) ac-
cording to local regulations.
 ► Age 18–85 years (inclusive).
 ► Documented or suspected infection: lung, abdominalor, in patients 
aged ≥65 years, urinary tract infection.
 ► Organ dysfunction defined as acute change in total Sequential 
Organ Failure Assessment score ≥2 points.
 ► Refractory hypotension requiring vasopressors to maintain MAP 
≥65 mm Hg despite adequate volume resuscitation (as per recom-
mendations of the Surviving Sepsis Campaign).
 ► Hyperlactataemia (blood lactate >2 mmol/L or 18 mg/dL). This cri-
terion must be met at least once for the purpose of diagnosis within 
the 24 hours before study drug administration.
Exclusion criteria
 ► Previous episode of septic shock requiring vasopressor administra-
tion within current hospital stay.
 ► Underlying concurrent immunodepression with anti- CD52 alemtu-
zumab or glucocorticoids >75 mg prednisone daily or equivalent for 
more than 7 days days.
 ► Immunosuppressive therapy related to recent (<6 months) 
transplantation.
 ► Cancer chemotherapy (<3 months) implying an immunodepression.
 ► Known HIV infection with low CD4 cell count (<200) for at least 6 
months.
 ► Known pregnancy (positive urine or serum pregnancy test).
 ► Shock of any other cause.
 ► Ongoing documented or suspected endocarditis, history of prosthet-
ic heart valves.
 ► Prolonged QT syndrome.
 ► End- stage neurological disease.
 ► End- stage cirrhosis (Child Pugh Class C).
 ► Acute Physiology and Chronic Health Evaluation score <15 or ≥34.
 ► Home oxygen therapy on a regular basis for >6 hours/day.
 ► Recent cardiopulmonary resuscitation (within current hospital stay).
 ► Body mass index ≥40 kg/m2 or weight ≥130 kg.
 ► Moribund patients.
 ► Decision to limit full care taken before obtaining informed consent.
 ► Participation in another interventional study in the 3 months prior 
to randomisation.
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Exploratory
 ► To evaluate PK/PD relationship to nangibotide- 
mechanism- of- action- related markers.
ASTONISH trial design
This is a multicentre randomised, double- blind, placebo- 
controlled dose- selection study in which two doses of 
nangibotide will be tested versus placebo. It will take 
place in approximately 50 centres in seven countries: 
France, Belgium, Denmark, Finland, Spain, Ireland and 
the USA. The study was initiated in November 2019. Addi-
tional sites may be added depending on recruitment rate.
Eligibility
All patients with a diagnosis of septic shock will be consid-
ered for study participation. The applicable local require-
ments for informed consent will be followed. All patients 
will receive standard of care for the treatment of septic 
shock.
After screening for eligibility by a central coordinating 
centre, patients meeting the inclusion and exclusion crite-
rion will be consented by the site team and randomised 
(box 1).
Study drug
All patients will be treated with standard therapy for 
septic shock. In addition, patients will receive a loading 
dose of nangibotide over fifteen minutes followed by infu-
sion at one of two doses (6.66 mg/kg+0.3 mg/kg/hour or 
20 mg/kg+1.0 mg/kg/hour) or a matched placebo.
Treatment with study drug must be initiated as early 
as possible, but no later than 24 hours after the onset of 
septic shock, defined by the start of vasopressor therapy. 
Blood samples for pharmacokinetic and exploratory 
pharmacodynamic analyses will be collected before, 
during and after the treatment period.
Patients will be treated for at least 3 days (72±2 hours) 
with study drug or until 24 (±2) hours after vasopressor 
withdrawal with a maximum treatment duration of 5 days 
(120±2 hours) (figure 1).
Blinding
ASTONISH is a double- blind trial. Study personnel 
including investigators, patients, sponsor and contracted 
research organisations will be blinded to treatment alloca-
tion until closure of the primary endpoint data set at day 
28. Unblinding will only take place if knowledge of the 
patient treatment allocation would facilitate emergency 
treatment. The investigational drug and the placebo are 
indistinguishable and presented in the same way.
Endpoints
Primary endpoint:
The primary endpoint is the change of total SOFA 
score from baseline to day 5, which will be assessed in the 
subgroup defined by patients with elevated sTREM-1 base-
line levels (≥400 pg/mL) and in the overall population.
Prespecified secondary endpoints will include:
Efficacy parameters:
Key secondary endpoint.
 ► All- cause mortality on day 28.
Secondary endpoints.
 ► Duration of Intensive Care Unit (ICU) stay, 
hospitalisation.
 ► Organ support- free survival.
 ► Daily change of total SOFA score and subscores
 ► Time until shock reversal defined as cessation of vaso-
pressor support for 24 hours
 ► Vasopressor use.
 ► Invasive mechanical ventilation.
 ► Renal support.
 ► Overall survival at 90 days, 6 and 12 months.
 ► Septic shock- related mortality up to 90 days, 6 and 12 
months.
 ► Incidence of secondary infections and postshock anti-
biotic use.
Safety parameters:
 ► Vital signs.
 ► ECG.
 ► Safety laboratory tests: haematology, coagulation, 
plasma biochemistry.
 ► Presence of antinangibotide antibodies.
 ► AEs, SAEs and deaths.
Pharmacokinetics:
Nangibotide plasma levels
Pharmacodynamics (exploratory): sTREM-1, immune 
and vascular- related biomarkers.
Pharmacoeconomic endpoints up to 12 months:
 ► Health- related quality of life (EQ- 5D).
 ► Postshock morbidity.
 ► Healthcare resource utilisation.
Figure 1 Study flow chart. CCC, Central Co- ordinating centre; EoS, end of study; Fu, follow- up; LD, loading dose or matching 
placebo.
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Patients will be assessed at the End of Study visit at 
day 28. After the last patient’s day 28 visit, the study data 
will be analysed. Additional follow- up (FU) visits will be 
conducted after 90 days, 6 and 12 months. Quality of life, 
morbidity and survival status of patients will be collected at 
these visits which may be undertaken remotely in order to 
minimise loss of patients to FU. Data from the long- term 
FU will be analysed and reported separately (a complete 
list of study investigations and their timing is presented in 
online supplemental files 1 and 2). Adverse event (AE) 
data will be collected until day 28, drug- related serious 
AEs (SAEs) can be reported without time limit.
sTREM-1 is a mechanism- based plasma marker associ-
ated with activation of the TREM-1 signalling pathway. 
As such it may be a biomarker predictive of treatment 
response to nangibotide. The plasma levels of sTREM-1 
will be determined at the second interim analysis and at 
the end of the study for the biostatistical analysis.
Randomisation and sample size
Following screening for eligibility, study centres will 
contact a central, independent coordinating centre to 
confirm eligibility. They will then be issued with a unique 
randomisation code that will facilitate identification of 
the correct blinded allocation of study drug.
The randomisation will be stratified according to site 
and patients will be allocated on a 1:1:1 basis to one of 
three treatment arms. The randomisation scheme will be 
generated by an independent statistician who is not part of 
the study team. A randomisation number will be assigned 
to each patient. The randomisation assignment will be 
implemented by an interactive response technology.
Results23 from a previous pilot phase II study (MOT- C-
201) have shown that a difference of around two versus 
placebo in mean changes of the primary endpoint 
(accounting for missing values occurring prior to day 5) 
and an SD of around 3.3, could be expected in the overall 
population, and even higher than two in the subgroup of 
patients with elevated sTREM-1 levels. It is expected that 
the high sTREM-1 subgroup will comprise at least half the 
patients enrolled (around 225 patients) in the study.
Considering 450 patients (150 patients per treatment 
arm), this study has at least 90% power to detect the 
expected difference in at least one dose either in the 
subgroup of patients with elevated sTREM-1 levels or in 
the overall population.
Analysis plan
This exploratory study has three parallel aims
 ► Assessment of the safety and tolerability of two doses 
of nangibotide.
 ► Assessment of the efficacy of two doses of nangibotide 
on the primary and secondary efficacy endpoints.
 ► Determining the best cut- off for baseline sTREM1 as a 
predictive biomarker.
The primary efficacy variable is the change of SOFA 
from baseline to day 5. This will be tested in the subgroup 
defined by patients with elevated sTREM-1 baseline levels 
and in the overall population. This will be based on an 
analysis of covariance model adjusting for randomised 
treatment and the baseline SOFA score.
The primary analysis will be undertaken in the modi-
fied intention to treat set (all randomised patients having 
received at least one dose of the prescription of study 
drug (either nangibotide or placebo).
Missing values occurring prior to day 5 are likely to be 
missing not at random and will be replaced as follows:
 ► Missing SOFA values not due to death will be replaced 
by the last available postrandomisation value of the 
SOFA score (ie, last observation carried forward 
method).
 ► Missing values due to death will be replaced by the 
last available postrandomisation value of the total 
SOFA score increased by an additional penalty of four 
points.
Sensitivity analyses using different penalty scores 
and other methods for handling missing data will be 
performed and described in the Statistical Analysis Plan 
(SAP).
This is a phase IIb trial, therefore, no adjustment for 
multiplicity will be proposed for the primary analysis 
and tests for nangibotide doses versus placebo compar-
isons will be performed at the usual nominal one- sided 
alpha level of 0.025 both in the subgroup and the overall 
population. However, a secondary adjusted analysis will 
be performed to account for multiplicity and control 
the overall one- sided error rate to 0.025: details will be 
further provided in the SAP before the unblinding of the 
database.
The key secondary endpoint of 28- day mortality will be 
assessed using a log- rank test to compare the treatment 
arms. In addition, a proportional hazard Cox model 
adjusting for the same covariates used for the primary 
endpoint analysis will be fitted to estimate the treatment 
effect.
Details of other endpoint analyses are described in the 
SAP.
The threshold for categorising high and low sTREM-1 
is defined as 400 pg/mL at baseline and is based on 
analysis of biomarker and outcome data from the phase 
IIa study.23 However, exploratory analyses based on the 
current study will be conducted to confirm the optimal 
cut- off for future studies.
After the first 113 (around 25%) and 225 (50%) patients 
have completed the 7- day period after randomisation, 
unblinded interim analyses of safety will be performed 
and the data reviewed by an independent data moni-
toring committee (DMC). The second interim analysis 
will, in addition, include an analysis of efficacy data, after 
which the DMC will make recommendations for stop-
ping the clinical trial or a treatment arm for futility (see 
online supplemental file 3 for DMC Charter). As well, if 
the proportion of patients with high sTREM-1 baseline 
values is less than 50% of the total, then the planned total 
sample size may be increased to maintain the power of 
the subgroup analyses. Data will be validated using on 
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research associates.
PATIENT AND PUBLIC INVOLVEMENT
No patient involved.
Ethics and dissemination
Ethical approval has been secured in Belgium, France, 
Denmark, Finland, Ireland and Spain in Europe and in 
the USA.
Consent for this study cannot be secured from a 
substantial proportion of eligible study participants due 
to lack of capacity associated with their diagnosis of septic 
shock. An emergency informed consent procedure will 
be applied according to applicable regulations and to 
the approval of the respective ethics committe or institu-
tional review board in patients who are assessed by their 
treating clinician as lacking capacity. Consent for further 
data/sample collection may be withdrawn by the patient 
at any time after they have regained capacity (an example 
consent form is provided in online supplemental file 4).
A manuscript with the results of the primary study will 
be published in a peer- reviewed journal and anonymised 
throughout. Separate manuscripts may be written on 
the secondary aims, and these will also be submitted for 
publication in peer- reviewed journals. Results will also be 
disseminated at national and international meetings (see 
online supplemental file 5) for Standard Protocol Items: 
Recommendations for Interventional Trials checklist).
DISCUSSION
This study has several novel components in terms of study 
design and analysis.
Nangibotide is the first compound to reach clinical trial 
that targets the critical TREM-1 pathway. This study will 
explore the efficacy of nangibotide in septic shock patients 
with elevated baseline levels of sTREM-1, a biomarker 
that reflects excessive activation of the target pathway and 
is associated with increased mortality. This approach may 
provide evidence for the design of a future phase III trial 
utilising a personalised, mechanism based biomarker to 
select patients likely to benefit from nangibotide.
In addition to selecting patients based on the clinical 
presentation of septic shock, this study employs additional 
prognostic enrichment by excluding those patients with 
Acute Physiology and Chronic Health Evaluation scores 
less than 15 or greater than or equal to 34 at baseline. 
This approach excludes patients at a low risk of death and 
those with a high estimated mortality (≥85%24 for whom 
nangibotide treatment is unlikely to be of benefit, reduces 
the outcome heterogeneity within the septic shock popu-
lation and increases the likelihood of detecting a clini-
cally relevant benefit.
The statistical analysis plan for this study includes 
the analysis of the primary endpoint in both the whole 
study population and the subgroup of patients with 
high sTREM-1 levels. This proposed stepwise analytical 
approach will offer adequate power to detect the efficacy 
of nangibotide in both patient groups while preserving 
confidence that a false positive result is unlikely .
The challenge of detecting clinically relevant benefit 
in phase II studies of novel therapeutic agents in septic 
shock is a substantial one which has been recognised by 
the clinical community25 and regulators.26 Change in 
SOFA, an established marker of the acute morbidity asso-
ciated with sepsis, has been consistently shown to act as a 
surrogate for subsequent mortality in septic shock.27 28 By 
incorporating robust guidelines for collection of clinical 
information and the handling of missing data,28 this study 
may improve the consistency and handling of data of this 
kind in randomised controlled trials.
Limitations of this phase IIb study include the use of a 
surrogate endpoint to detect clinically relevant efficacy. 
While the change in SOFA score has been extensively 
validated, further studies will be required to demonstrate 
improved mortality as a primary outcome. Furthermore, 
by defining a priori the subgroup of patients with elevated 
sTREM-1 levels as those most likely to benefit, the avail-
able statistical power to detect a benefit only in those 
patients with low sTREM-1 levels at baseline is reduced.
Specific treatments for septic shock have remained 
elusive and given the increasing prevalence, substan-
tial mortality and morbidity that is associated with it, 
the demand for novel therapies to treat the condition 
continues to be high. With increasing recognition that 
a variety of endotypes exist within the population char-
acterised by the standard definitions,29 30 novel agents 
targeting subgroups most likely to benefit from treat-
ment offer an attractive approach. Nangibotide is the first 
agent to target the TREM-1 pathway in patients, and the 
ASTONISH trial will provide valuable insights into both 
the safety and efficacy of this novel therapy in the treat-
ment of patients with septic shock.
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